Get started

CC

$PLFX beyond TA, notes from the June 22nd Shareholder CCBLUF: PLFX will be making some huge PR notification in July as Jordan Fiksenbaum establishes his position as the CEO and Pulse Evolution takes on Las Vegas with its holographic live performances. Expect move up to QB then big boards. PLFX CC June 22, 2017 Caveat – finances, expenses cab be different when audited – GAAP or non—GAAP Revenue activity has commenced! Alpha Test of Michael Jackson showed, the process needed better technology. Much better today than in 2014. We are among global leaders in this technology. Why the CC now? We feel we are at the Inflection Point. From a Start-up to a Global Entertainment Company. From a developer to a monetizer of our technology. The hire of Jordan NOW confirms the point of inflection has arrived. Working together with AR, VR and AI. PLFX entertainment applications include: On stage ( concert tours / theatrical exhibitions) Games VR Rev’s will come in bunches. Series of announcements coming in coming quarter. Our raising of financials has been successful. Since 2014 about $40 mil. Mostly from shareholders – including favourable shareholder debt. Cash-bur rate has been reduced. Now, ready to start productions w/repeatable revenues in mind. July 1 to Sept. 30, 2016 $3.5 mil deficit and 2 mil/mo. Cash burn rate. 2nt Quarter 2017: 1.8 mil cash receipts. 1.25 mil were producer fees, a very efficient way of sharing fees and responsibilities with co-producers, who bring a great deal of experience in live entertainment. $400k in animation, Fantasy Popstars in Korea. Our first Animation. $270k from living celebrity – can’t mention name, but TOP in the world today – eager to have his “digital likeness” established by us. No rev. in current quarter – still more efficient cash deficit. Focus on next month. (Mentioned here Pulse Biologic, a Subsidiary) Expecting small profit starting July, which will help with overhead. Our issue is sustainability and monetization of our technology. Michael Jackson (Estate) Production activity was visible in 2017. We have a powerful, long-term relationship with them re: digital rights. The estate has the option to buy the digital rights in the future. MJ = Global Distribution. Elvis is still in negotiations. Working on contracts – hoping it will be similar to MJ Estate, with fixed revenue sharing, instead of % of rev’s. Response to questions about ABBA – Let Simon Fuller build that property. PLFX still has proprietary rights, but traditionally (as we did with Cameron during film Titanic), Tech. Co.’s stay in background and do not get ahead of celebrities. We defer to Fuller and Universal Co. re: announcements. Relationship still important. Large scale celebrity-based production (July) will be global ( again the inflection point). In House Production, goal is to push the evolution of our Technology. Management – we have become active in recruiting top talent- Jordan had over $5 bil. in sales – the fact that he is joining us NOW underlines the inflection point. HE was a long-time Non-Fiduciary Board of Advisors Member – now becoming active. He will have a broad mandate, stressing timeliness of reports. Our principle currency will be the US Market. Since Jan. 2015, focused on Big Productions. Had disadvantages – lots of work, development – didn’t always lead to delivery of product. Co-production helps to eliminate these disadvantages. PLFX will have multiple “small pieces” of many pies. (Compare to franchising?) Move up to QB next goal, then onward after that. Up till now, we have been rather quiet, but now it’s time to talk. Shareholders will be hearing from us (Jordan) over the next weeks. Debt is almost 100% shareholder. 8.9 million, of which 2.5 presently converting at $1. PLFX has $600l in secured debt.
OTC:PLFXLong
by Ronin4nana
CC - Upward channel breakdown short from $38.13 to $30.74 CC seems breaking down from longer term upward channel. It has a lot of insider selling, and P/E ratio of 72.33, where Debt to Equity is very high 10.06. We think it has good down-side potential. * Trade Criteria * Date First Found- June 6, 2017 Pattern/Why- Fallen angel pattern Entry Target Criteria- Break of $38.13 Exit Target Criteria- $30.74 Stop Loss Criteria- $42.17 Please check back for Trade updates. (Note: Trade update is little delayed here.)
NYSE:CCShort
by AcornWealthCorp
NEXT WEEK'S COVERED CALL CANDIDATES: ZIOP, NVAX, LC, WLLHere's my "short list" for covered call candidates for next week generated by looking at Barcharts.com high volatility stock options list and the Dough grid: WLL buy shares at 7.66; sell Sept 16th 8 call; 7.10 debit; $90 max profit (12.7% ROC) CC buy shares at 11.45; sell Sept 16th 12 call; 10.78 debit; $122 max profit (10.6% ROC) LC buy shares at 5.40; sell Oct 21st 5.5 call; 4.85 debit; $65 max profit (13.4% ROC) ZIOP buy shares at 5.46; sell Oct 21st 6 call; 4.65 debit; $135 max profit (29.0% ROC) NVAX buy shares at 7.04; sell Oct 21st 8 call; 5.42 debit.; $258 max profit (47.6% ROC) FCX buy shares at 11.92; sell Sept 30 12 call; 10.90 debit; $102 max profit (9.3% ROC) JCP buy shares at 10.55; sell Sept 30th 11 call; 9.59 debit; $96 max profit (9.6% ROC) Notes: (1) WLL's a petro play. Because so many small petro companies are in trouble of one kind or another (i.e., shale and/or offshore oil exploration exposure), I generally prefer playing something with a little less "single company exposure" (e.g., XOP). But, hey, it meets my general rule of >10% ROC. (2) CC is a basic materials/chemical play. It spun off from DuPont and has had quite an up run here in spite of a recent punitive damages judgment for chemical dumping (weirdly, the stock dipped and then subsequently popped on the news, probably out of relief that the debacle was in the rear view mirror). (3) LC's been in a downtrend since IPO. At best, a money, take, run play. (4) I still like ZIOP. It's biopharma and has a fairly diverse pipeline such that if one drug fails, they still have more in the hopper. And that 29% ROC, well ... drop dead gorgeous if it can get to $6. (5) I'm also in NVAX (biopharm). In comparison to ZIOP, their pipeline is quite narrow and currently devoted to a single vaccine (RSV). sg.finance.yahoo.com (vaccine "could be breakthrough," but not time to "break out the champagne" (code for "it could suck ... or not")). (6) FCX (mining). I covered called this in late 2015, early 2016 which commodities were at a cyclical low and then bailed out when it appeared to be topping. Looking back, it kind of looks pricey here in comparison, and I'm not so hot on the ROC. However, it's highly liquid, and it has some room to pop to 14.00 resistance (and naturally some room to cave; the 2016 low is sub-$4). (7) JCP. Well, it's JCP. Plus, it's had a bit of a run up here, and if past performance is indicative of future results, well, it could zombie trade back to sub-$9 and with the ROC, well, not at the top of my list ... .
WLong
by NaughtyPines
Change buy from neutral as strong support was found on trendlinePro Long: - Trend line provided massive support (dark red line) - High volume at support and during the rally - future spreads very strong (N16-U16 turned into backwardation) - If we close positive today 7 MA will cross 20 MA generating buy signal Contra Long: - running into resistance on middle Bollinger Band (20 day MA) I sold the 2900 puts last week as a sideways prediction was put in place and will keep that position and add once I see a pull back into the lower trend line
CLong
by mjhillpp